# Ribonexus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ribonexus

- Industry: Biotechnology
- Headquarters: France
- Total disclosed funding: $2.4M
- Latest round: Seed (Sep 10, 2021)
- Investors on record: 3

## About

Based in France, Aglaia Therapeutics operates as a biotechnology company that creates medicines for cancer patients who are receiving targeted therapy. The company was co-founded by Advent France Biotechnology, Alejo Chorny, and Institut Curie, and Gustave Roussy. In September 2021, Aglaia Therapeutics raised its latest Seed funding from a group of investors that includes Advent France Biotechnology, Crédit Mutuel Innovation, and Pierre Fabre.

The company offers oncology therapies that aim to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who develop resistance to these kinds of treatments. The therapy targets mRNA translation through an acquisition of a product from Pierre Fabre.

The company plans to use the latest Seed funding to prepare its preclinical development program.

## Funding rounds

- Seed, Sep 10, 2021, $2.4M — Credit Mutuel Equity, Pierre Fabre, AdBio Partners

## Investors

- Credit Mutuel Equity (https://capitalatlas.ai/funds/credit-mutuel-equity) — Seed
- Pierre Fabre — Seed
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed